COVID-19 vaccine-readiness for ocrelizumab and other
anti-CD20-depleting therapies in multiple sclerosis and other autoimmune
diseases
David Baker1, Charles AK Roberts1,
Gareth Pryce1, Angray S Kang1,2,
Monica Marta1,3, Saul Reyes1,3,
Klaus Schmierer1,3, Gavin
Giovannoni1,3, Sandra Amor1,4
1. Blizard Institute, Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, London E1 2AT,
United Kingdom.
2.Centre for Oral Immunobiology and Regenerative
Medicine, Institute of Dentistry, Barts and The London School of
Medicine and Dentistry, Queen Mary University of London, United Kingdom
3.Clinical Board: Medicine (Neuroscience), The Royal
London Hospital, Barts Health NHS Trust, London, United Kingdom
4.Pathology Department, Amsterdam UMC, VUmc site,
Amsterdam, The Netherlands
Running head: Vaccine readiness of ocrelizumab
Corresponding author:
Prof. David Baker; BartsMS, Blizard Institute, Barts and the London
School of Medicine and Dentistry, Queen Mary University of London, 4
Newark Street, London E1 2AT. Tel: +442078822485; Fax: +442078822180;
Email:david.baker@qmul.ac.uk
s.amor@amsterdamumc.nl (S. Amor). Neuropathology, Dept Pathology,
Amsterdam UMC Locatie VUmc, ZH 2E 49, De Boelelaan 1117, 1081 HV
Amsterdam, The Netherlands